Evidence & concentration worksheet · Healing & Recovery
Cartalax 20 mg
Human efficacy and a validated dose have not been established for this compound. The former regimen has been withheld; only concentration arithmetic remains available.
Evidence review
No established human dosing protocol
Human efficacy and a validated dose have not been established for this compound. The former regimen has been withheld; only concentration arithmetic remains available.
How it works
Cartalax is the synthetic tripeptide AED (Ala-Glu-Asp) marketed as a cartilage “bioregulator.” It has no FDA-approved product, indication, or dose.
Benefits & side effects
Recent work examined AED in cultured rat chondrocytes and stem-cell differentiation models.[1][2] No controlled human trial establishes Cartalax for osteoarthritis, pain, cartilage regeneration, mobility, or aging. A change in cultured-cell proliferation does not show that cartilage regrows inside a loaded human joint.
Calculator
Concentration and measurement calculator
Use this only to check arithmetic from an authoritative product label, registered study protocol, or qualified clinician.
Arithmetic only — not a dose recommendation
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Source concentration
Source-supplied target
References
References
- Vrach — AED in cultured chondrocytes from young and old rats (2023)
- International Journal of Molecular Sciences — Peptide regulation of chondrogenic stem-cell differentiation (2023)
- U.S. FDA — Understanding the risks of compounded drugs (2026)